PROK PROKIDNEY CORP.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1850270 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.2%
TTM net income YoY-45.4%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-24,830.3%
Net margin-13,326.7%
FCF margin-21,655.0%
EBITDA margin-24,002.1%
Returns
ROE—
ROA-36.8%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets15.8%
Debt / equity—
Current ratio5.04x
Interest coverage-10,690.83x
Cash quality & payout
Operating cash flow / net income1.48x
Accruals ratio17.8%
Payout ratio—
Capex / revenue1,884.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY2022*2022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $893,000 | $76,000 | $0 | $0 | — |
| R&D expense | $114.12M | $127.67M | $106.71M | $82.07M | $46.26M |
| SG&A expense | $51.78M | $56.08M | $44.81M | $70.94M | $8.86M |
| Operating income | -$165.01M | -$183.68M | -$151.52M | -$153.01M | -$55.11M |
| Interest expense | $4,000 | $9,000 | $12,000 | $215,000 | $0 |
| Pretax income | -$151.20M | -$163.93M | -$129.45M | -$147.24M | -$55.11M |
| Income tax | $414,000 | -$598,000 | $6.00M | $896,000 | $38,000 |
| Net income | -$68.99M | -$61.19M | -$35.47M | -$148.13M | -$55.15M |
| EBITDA | -$158.43M | -$178.24M | -$147.67M | -$149.97M | -$53.13M |
| EPS (basic) | — | — | — | -0.23 | — |
| EPS (diluted) | — | — | — | -0.23 | — |
| Weighted avg. shares (diluted) | — | — | — | 61.54M | — |
| Balance sheet | |||||
| Cash & equivalents | $108.54M | $99.12M | $60.65M | $490.25M | $20.56M |
| Current assets | $280.68M | $395.88M | $374.15M | $504.72M | $27.27M |
| PP&E, net | $51.23M | $42.22M | $42.14M | $10.71M | $11.36M |
| Intangibles | — | — | $0 | $213,000 | $428,000 |
| Total assets | $335.57M | $441.07M | $420.55M | $518.00M | $40.30M |
| Current liabilities | $30.74M | $36.22M | $25.04M | $10.87M | $12.31M |
| Total liabilities | $34.78M | $39.44M | $29.22M | $13.06M | $13.38M |
| Shareholders' equity | -$1.01B | -$994.95M | -$1.10B | -$1.10B | $26.92M |
| Cash flow statement | |||||
| Operating cash flow | -$120.12M | -$126.35M | -$90.07M | -$77.09M | -$50.30M |
| Capital expenditure | $15.20M | $29.51M | $34.20M | $1.85M | $5.19M |
| Free cash flow | -$135.31M | -$155.86M | -$124.27M | -$78.94M | -$55.49M |
| Investing cash flow | $103.97M | $20.41M | -$329.98M | -$1.74M | -$5.19M |
| Financing cash flow | $25.57M | $144.41M | -$9.55M | $548.52M | $71.47M |
| Depreciation & amortization | $6.58M | $5.43M | $3.85M | $3.04M | $1.98M |
| Stock-based compensation | $25.34M | $29.37M | $30.85M | $74.47M | $699,000 |
| Share buybacks | $0 | $0 | $9.50M | $0 | $0 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.